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Abstract: Soft tissue sarcoma (STS) comprises a large variety of rare malignant tumors. 
Development of distant metastasis is frequent, even in patients undergoing initial curative 
surgery. Trabectedin, a tetrahydroisoquinoline alkaloid isolated from the Caribbean marine 
tunicate Ecteinascidia turbinata, was approved in 2007 for patients with advanced STS 
after failure of anthracyclines and ifosfamide, or for patients unsuited to receive these 
agents. In this study, we retrospectively analyzed 25 patients who had been treated with 
trabectedin at our institution between 2007 and 2010. The majority (72%) had been heavily 
pre-treated with 2 previous lines of chemotherapy. Response assessed by conventional 
RECIST criteria was low, with only one patient achieving a partial remission (PR) and 10 
stable disease (SD) after three cycles of treatment. However, median progression-free 
survival (PFS) and overall survival (OS) were significantly prolonged in this population 
compared to non-responders, with 7.7 months versus 2.1 months (p < 0.0001; HR 15.37, 
95% CI 4.3 to 54.5) and 12.13 months versus 5.54 months (p = 0.0137; HR 3.7, 95% CI 
1.3 to 10.5), respectively. PFS for all patients was 58% at three months and 37% at six 
months. Side effects, including neutropenia, elevation of liver transaminases/liver function 
tests, and nausea/vomiting, were usually mild and manageable. However, dose reductions 
due to side effects were necessary in five patients. We conclude that trabectedin is an 
effective and generally well tolerated treatment for STS even in a heavily pre-treated 
patient population. 
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1. Introduction 
Soft tissue sarcoma (STS) are a heterogeneous group of rare malignant tumors, predominantly 
arising from the embryonic mesoderm. For 2008, there were an estimated 10,390 new diagnoses and 
3,680 deaths due to STS in the United States [1]. Because of treatment complexity, STS require a 
multidisciplinary approach in a specialized center involving oncologic surgeons, sarcoma pathologists, 
radiation therapists and medical oncologists. The mainstay of curative treatment is complete surgical 
resection with negative histological margins. However, development of distant metastases remains the 
major problem in up to 50% of all STS patients [2]. Prognosis for those individuals with advanced and 
unresectable disease is grim with a median survival of eight to 13 months from the start of first-line 
chemotherapy, usually doxorubicin and/or ifosfamid based regimens [3]. Response by conventional 
Response Evaluation Criteria in Solid Tumors (RECIST criteria) to those regimens is approximately 
20–30% [4].  
Trabectedin (Ecteinascidin-743 [ET-743], Yondelis®) is a tetrahydroisoquinoline alkaloid isolated 
from the Caribbean marine tunicate, Ecteinascidia turbinata, which binds through the minor groove of 
DNA at guanine nucleotides of specific sequences [5]. This new compound was approved in 2007 for 
second-line treatment of advanced STS in the European Union. Phase II studies identified 1.5 mg/m² 
of trabectedin via 24-hour continuous intravenous (IV) infusion every three weeks as the optimal 
regimen. Overall response by RECIST criteria was low with only 4–17%. However, the six months 
progression free survival (PFS) was favorably comparable to other clinically used second-line 
treatments [6–8]. Interestingly, distinct histological subtypes seem to show major response rates to 
trabectedin, e.g., myxoid liposarcoma, expressing the chimeric FUS-CHOP fusion protein, and 
leiomyosarcoma [9,10]. Here we present a retrospective analysis of our experience treating STS 
patients with trabectedin.  
2. Patients and Methods 
2.1. Patients and Eligibility Criteria  
All patients with metastatic STS treated at our institution between January 2007 and March 2010 
were identified and retrospectively analyzed reviewing electronically filed patients’ charts. Eligibility 
criteria included histologically proven STS and failure of standard first-line doxorubicin- and/or 
ifosfamid-containing chemotherapy regimens. Tumor specimens were classified according to the 
Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system. Patients with Ewing’s 
sarcoma or osteosarcoma were excluded from this analysis. Before start of treatment, and before 
continuing treatment with the subsequent cycle, the following criteria as defined by the manufacturer’s 
summary of product characteristics (SPC) were required: absolute neutrophile count   
(ANC)  > 1.500/µL; platelets > 100,000/µL, bilirubin < upper limit of normal (ULN); alkaline 
phosphatase (AP) ≤ 2.5× ULN; alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ Mar. Drugs 2010, 8                 
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2.5×  ULN; creatinine clearance ≥ 30 mL/min, haemoglobin ≥ 9 g/dL, albumin > 25 g/L; 
creatine phosphokinase (CPK) ≤ 2.5 × ULN. 
2.2. Trabectedin 
After obtaining written informed consent, trabectedin was administered as a 1.5 mg/m
2 24-hour 
continuous IV infusion every three weeks. Drug administration through an implantable port-catheter 
system or central venous line was mandatory by internal Standard Operating Procedures (SOPs). 
Premedication with dexamethasone 20 mg IV, 30 minutes prior to trabectedin, was mandatory. 
Antiemetic prophylaxis according to internal SOPs was administered with granisetron 2 mg po once 
daily on days 1 and 2. Treatment with trabectedin was discontinued at progression, in case of 
unacceptable toxicity or at the patient’s request.  
2.3. Imaging Studies and Restaging 
Assessment of tumor progression according to RECIST criteria [11] was performed after every  
3 cycles of treatment or on finding clinical signs of progression by magnetic resonance imaging (MRI) 
and/or CT scans of primary tumor site and sites of metastases. Response to treatment was defined as 
complete remission (CR), partial remission (PR) or stable disease (SD).  
2.4. Toxicity Assessment 
Major clinical toxicities occurring after trabectedin were collected by chart review focusing on 
hematological toxicity, nausea/vomiting and changes in liver function tests. Dose limiting toxicities 
according to the manufacturer’s SPC: ANC < 500/µL for more than five days or neutropenia 
associated with fever/infection; thrombocytopenia < 25.000/µL; bilirubin > ULN; AP > 2.5× ULN;  
AST/ALT > 2.5× ULN. Dose reductions were performed if any of the above mentioned events 
occurred. Adverse events were graded according to Common Terminology Criteria for Adverse Events 
v4.0 (CTCAE), published May 28, 2009, by the National Cancer Institute (NCI). Patient charts were 
also reviewed for reports of drug extravasation including skin or soft tissue damage. 
2.5. Statistical Analysis 
Surviving patients were censored at the date of last follow up. Progression free survival (PFS) and 
overall survival (OS) were estimated using the method of Kaplan and Meier. PFS was defined as the 
time interval from the date of therapy induction to radiologically proven disease progression or 
patient’s death due to sarcoma related cause. Cause of death (COD) was determined by principal 
investigator (TS) by chart review and autopsy reports. OS was defined as the time interval from the 
date of therapy induction to patient´s death or last follow up. Statistical testing was done using the 
Logrank test. Significance levels were set at 0.05. Calculations were performed using Medcalc 
software (release 11; Mariakerke, Belgium). Data was analyzed as of May 04, 2010 Mar. Drugs 2010, 8                 
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3. Results and Discussion 
3.1. Patient Characteristics  
Between 2007 and 2010, 25 patients (male = 14, female = 11, median age 51 years [range 16–71]) 
with STS were treated at our institution. One heavily pre-treated patient with Ewing´s sarcoma 
received trabectedin resulting in disease progression after two cycles and was not included in this 
analysis. Nine patients (Pat. 016, 017, 018, 019, 021, 022, 023, 024, 025) were still alive at the date of 
data analysis with one subject (Pat. 023) still continuing treatment with trabectedin. Histological 
subtypes comprised leiomyosarcoma (n = 10), liposarcoma (n = 5), pleomorphic sarcoma (n = 3), 
synovial sarcoma (n = 3), rhabdomyosarcoma (n = 2) and other subtypes (n = 2) with tumor grades 
being G1 (n = 3), G2 (n = 4) and G3 (n = 18). No information on chromosomal aberrations or fusion 
products was available for any patient. Primary tumor sites included abdomen/retroperitoneum 
(n = 12), extremities (n = 9), trunk (n = 3), and head/neck (n = 1). Metastases were found in lung 
(n = 17), lymph nodes (n = 7), soft tissue/solid organs (n = 15) and bone (n = 4). Patients had received 
1 (n = 7), 2 (n = 10) or ≥3 (n = 8) previous lines of chemotherapy. A total number of 103 cycles were 
administered with a median number of four cycles (range 1–12) received by each patient. No patient 
underwent further surgery after administration of trabectedin. Patient characteristics are summarized in 
Table 1. 
3.2. Response Assessment 
Best response by RECIST criteria after three cycles of treatment were PR (n = 1) and SD (n = 10). 
Primarily progressive disease was seen in 14 patients. Two patients (Pat. 017 and UPN 018) 
discontinued treatment after six and 12 cycles of therapy achieving SD. Median PFS and OS for the 
whole population were 3.7 and 8.8 months, respectively. PFS at three and six months was 58% and 
37% (Figures 1 and 2). However, patients responding to therapy (defined as PR or SD after three 
cycles of treatment with trabectedin) had a significantly longer median PFS and OS with 7.7 months 
versus 2.1 months (p < 0.0001; HR 15.37, 95% CI 4.3 to 54.5) and 12.13 months versus 5.54 months 
(p  =  0.0137; HR 3.7, 95% CI 1.3 to 10.5) (Figure 3 and 4). In general, response assessment by 
different histological subsets was not possible due to small patient numbers. However, comparing 
patients with leiomyosarcoma versus other histological subtypes, we found a significant difference in 
median OS (10.8 vs. 7.8 months; p = 0.01; HR 4.5, 95% CI 1.4 to 14.4) but not in PFS (3.7 vs. 
2.9 months;  
p = 0.14). Comparing PFS and OS in G1 versus G2/3 tumors and 1–2 versus ≥3 previous lines of 
chemotherapy, respectively, we found no statistically significant differences.  
 Mar. Drugs 2010, 8                 
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Table 1. Patient characteristics. 
Patient Age  Gender  Histology  Grading Primary  tumor Metastases  Previous 
CTX lines 
#Cycles  Staging   PFS (in days)  OS (in days)  Complications  Alive  COD 
001  71  M  Spindle cell sarcoma  G3  Trunk  S  2  2  PD  21 64 None  No  Progression 
002  64  M  Leiomyosarcoma  G3  Extremity    P  2  2  PD  23 48 None  No  Progression 
003  36  F  Liposarcoma G2  Abdomen  S,  P  2 3  SD  145 255 None  No  Progression 
004  16  F  Synovial sarcoma  G3  Trunk  S, P  6  1  PD  23  44  None  No  Progression 
005  53  F  Liposarcoma G3  Retroperitoneum  S 3 3  PR  236 289 None  No  Progression 
006  55  M  Pleomorphic Sarcoma  G3  Extremity   P, S  3  3  PD  87  139  None  No  Progression 
007 56  M  Pleomorphic  Sarcoma  G3  Abdomen  P 2 5  PD  110 269 None  No  Progression 
008  29  F  Leiomyosarcoma  G3  Abdomen  S, P  4  3  PD  86  169  N/V, liver tox  No  Progression 
009  46  M  Myxoid Liposarcoma  G1  Extremity   S, B  2  5  SD  114  183  None  No  Progression 
010  56  F  Leiomyosarcoma  G3  Abdomen  S,  P  2 7  SD  216 370 None  No  Progression 
011 58  M  Liposarcoma  G3  Retroperitoneum S  3  3  PD  55  238  None  No  Progression 
012  37  M  Leiomyosarcoma  G3  Abdomen  S, P, L  1  6  SD   113  178  None  No  Progression 
013  57  M  Synovial sarcoma  G3  Extremity   P, L  3  1  PD  20  25  None  No  Progression 
014 70  F  Leiomyosarcoma  G3  Abdomen  P  2  3  PD  66  297  N/V  No Progression 
015  49  F  Leiomyosarcoma  G2  Abdomen  S, P, L  1  2  PD  57  328  N/V  No  Progression 
016  49  F  Leiomyosarcoma  G1  Abdomen  P 1 8  SD  182 240 hem  tox  Yes   
017  64  M  Leiomyosarcoma  G2  Extremity   P, B  4  6  SD  309  309  hem tox  Yes   
018  49  F  Leiomyosarcoma  G3  Abdomen  S 2 12  SD  266 266 None  Yes   
019  53  M  Leiomyosarcoma  G2  Extremity   S, B  2  3  PD  75  237  hem tox  Yes   
020  49  M  Synovial sarcoma  G3  Trunk  P, L  1  1  PD  41  65  liver tox  No  Progression 
021  31  F  Pleomorphic Sarcoma  G3  Abdomen  L, B  2  3  PD  70  212  N/V  Yes   
022  71  M  Liposarcoma  G3  Extremity   S, P  3  8  SD  181  205  hem tox  Yes   
023 58  M  Rhabdomyosarcoma  G3  Head/Neck  L 1 5  SD  105 105 None  Yes   
024  24  F  Fibromyxoid sarcoma  G1  Extremity   S, P  1  5  SD  151  188  None  Yes   
025  64  M  Rhabdomyosarcoma  G3  Extremity   P, L  1  3  PD  89  89  None  Yes   
Abbreviations: B = bone metastasis; Dx = diagnosis; COD = cause of death; F = female; Hem tox = hematological toxicity; Liver tox = liver toxicity; M = male; N/V = nausea/vomiting; OS = overall survival;  
P = pulmonary metastasis; PD = progressive disease; PFS = progression-free survival; PR = partial remission; S = soft tissue/solid organ metastasis; SD = stable disease. Mar. Drugs 2010, 8                 
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Figure 1. Progression-free survival for all patients. Progression-free survival (months) 
from start of trabectedin to disease progression was estimated using the method of Kaplan 
and Meier.  
 
Figure 2. Overall survival for all patients. Overall survival from the start of trabectedin to 
disease progression (months) was estimated using the method of Kaplan and Meier.  
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Figure 3. Progression-free survival in responders vs. non-responders. Progression-free 
survival (months) from start of trabectedin to disease progression was estimated using the 
method of Kaplan and Meier. Responders (dotted line), defined as CR, PR or SD after 
three cycles of treatment, showed significantly prolonged PFS compared to non-responders  
(solid line). 
 
Figure 4. Overall survival in responders vs. non-responders. Overall survival (months) 
from the start of trabectedin to death was estimated using the method of Kaplan and Meier. 
Responders (dotted line), defined as CR, PR or SD after three cycles of treatment, showed 
significantly prolonged OS compared to non-responders (solid line). 
 Mar. Drugs 2010, 8                 
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3.3. Toxicity Assessment 
Major toxicities included nausea/vomiting CTC grade ≥ 2 (n = 4), neutropenia (n = 4) and elevation 
of liver transaminases > 2.5× ULN (n = 2), leading to dose reductions in five patients. One patient who 
developed elevation of liver transaminases had concomitant radiological disease progression and 
therefore did not receive further treatment with trabectedin. Skin or soft tissue damage due to drug 
extravasation was not observed in any patient. No patient discontinued treatment due to unacceptable 
toxicities. 
3.4. Discussion 
Treatment of metastatic STS is challenging and outcome is frequently grim. Therefore, new 
therapeutic targets and compounds are urgently needed. Trabectedin was approved in 2007 for patients 
with advanced STS after failure of anthracyclines and ifosfamide, or those who were unsuited to 
receive these agents. In this study we retrospectively analyzed 25 patients treated at our institution. 
Only seven out of 25 patients (28%) received trabectedin as second-line therapy. The majority (72%) 
had been heavily pre-treated with 2 previous lines of chemotherapy. Conventional first-line 
chemotherapy with doxorubicin and/or ifosfamide containing regimens results in radiological response 
rates of approximately 20–30%. However, there has been an ongoing debate whether RECIST criteria 
reflect the specific biology of STS [12,13]. Van Glabbeke et al. suggested already in 2002 to use PFS 
rates at six and three months instead of tumor response by RECIST criteria to assess drug activity in 
clinical trials [14]. Based on the success of functional imaging in gastrointestinal stroma tumors 
(GIST), approaches with fluorine-18-fluorodeoxyglucose PET (FDG-PET) and diffusion weighted 
MRI scans [15–17] have been explored in STS to assess treatment response. Data on the usefulness of 
functional imaging in patients treated with trabectedin is scarce. Our own group reported on nine 
patients monitored with FDG-PET [18]. In this small series, stabilization of standardized uptake values 
(SUV) was observed in nearly all patients. One patient with morphologic PR showed a 40% decrease 
in SUV. However, further studies are needed to validate those results.  
As seen in previous studies with trabectedin, our current series confirms that radiological response 
by RECIST criteria is low. Only one patient (4%) achieved PR after three cycles of treatment. 
However, tumor control was obtained in a further 10 patients (40%) achieving SD, leading to a median 
PFS of 7.7 months and median OS of 12.13 months in this group. PFS at six months for the whole 
population was 37% and median PFS 3.7 months. Statistical testing might be slightly influenced by the 
fact that at the date of data analysis nine patients were still in follow up. However, our results are 
comparable to other clinically used second-line treatments for metastatic STS and the previously 
published phase II studies with trabectedin. Here, PFS rates of 24–29% at six months and a median 
PFS of 1.7–3.4 months, respectively, were reported [6–8]. Further reports of trabectedin in routine use 
confirm our results [19,20]. 
Other commonly used second-line regimens include gemcitabine or gemcitabine plus docetaxel. 
However, these agents have not been officially approved for the treatment of metastatic STS. For 
gemcitabine monotherapy, a PFS rate of 13.3% has been reported at six months [21], which is slightly 
below the suggested 14% to assess drug activity at this time point as reported by Van Glabbeke et al. 
[14]. Furthermore, the additional effect of docetaxel has been questioned. Maki  et al. reported a Mar. Drugs 2010, 8                 
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median PFS of 6.2 months for the combination regimen and 3.0 months for gemcitabine monotherapy 
[22]. In contrast, Duffaud et al. concluded that there was no benefit for the combination regimen as 
median PFS was 5.5 months for gemcitabine alone versus 3.4 months for gemcitabine plus docetaxel 
[23]. However, response may differ in histological subsets.  
Trabectedin does not act exclusively as a minor groove DNA binder, but has additional effects at 
the transcriptional level [24]. Exploiting these additional molecular properties of trabectedin, 
combination regimens with doxorubicin have been tested with preliminary promising results [25,26]. 
Furthermore, this might explain its particular activity in myxoid liposarcoma (MLS) characterized by 
the translocations t(12;16)(q13;p11) or t(12;22)(q13;q12) resulting in the formation of FUS-CHOP and 
EWS-CHOP fusion proteins, respectively. A superior overall response rate of 51% with a median PFS 
of 14 months and a PFS rate of 88% at six months was demonstrated [9]. In vivo, maturation of MLS 
lipoblasts after treatment with trabectedin has been shown, elucidating the underlying 
pathophysiological pathways [27]. Unfortunately, patient numbers in our series were too small to 
statistically assess response by different histological subtypes. One subject (Pat. 009) with MLS 
showed disease progression after five cycles of treatment. For patients with leiomyosarcoma, we found 
no statistically significant difference in median PFS. However, this subgroup showed improved 
median OS. In previous studies, distinct susceptibility to trabectedin in this histological subtype was 
suggested [10]. Most probably due to the small patient number, we were not able to reproduce 
these results. 
The rate of major toxicities and adverse events was low in our retrospective analysis and in line 
with the manufacturer’s SPC. As administration through a port-catheter system or central venous line 
was mandatory due to internal SOPs, no patient experienced drug extravasation. However, there have 
been reports of skin and soft tissue damage [28].  
4. Conclusion 
Trabectedin is a generally well tolerated and effective treatment for STS even in a heavily 
pre-treated patient population. Major toxicities include neutropenia, changes in liver function tests and 
nausea/vomiting. Dose reductions usually allow continuation of treatment. Response by conventional 
RECIST criteria is low. However, progression-free survival and overall survival were significantly 
prolonged in responders and seem not to be inferior to other clinically used second-line treatments for 
the whole patient population. 
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